243 related articles for article (PubMed ID: 33891949)
1. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
Arvind A; Memel ZN; Philpotts LL; Zheng H; Corey KE; Simon TG
Metabolism; 2021 Jul; 120():154780. PubMed ID: 33891949
[TBL] [Abstract][Full Text] [Related]
2. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
[TBL] [Abstract][Full Text] [Related]
3. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
4. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.
van Dalem J; Driessen JHM; Burden AM; Stehouwer CDA; Klungel OH; de Vries F; Brouwers MCGJ
Hepatology; 2021 Nov; 74(5):2467-2477. PubMed ID: 34129693
[TBL] [Abstract][Full Text] [Related]
6. Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study.
Lee JY; Jang SY; Nam CM; Kang ES
Sci Rep; 2019 Jun; 9(1):8532. PubMed ID: 31189966
[TBL] [Abstract][Full Text] [Related]
7. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.
Donadon V; Balbi M; Casarin P; Vario A; Alberti A
World J Gastroenterol; 2008 Oct; 14(37):5695-700. PubMed ID: 18837086
[TBL] [Abstract][Full Text] [Related]
8. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
9. Oral agents in the management of type 2 diabetes mellitus.
Luna B; Feinglos MN
Am Fam Physician; 2001 May; 63(9):1747-56. PubMed ID: 11352285
[TBL] [Abstract][Full Text] [Related]
10. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.
Hassan MM; Curley SA; Li D; Kaseb A; Davila M; Abdalla EK; Javle M; Moghazy DM; Lozano RD; Abbruzzese JL; Vauthey JN
Cancer; 2010 Apr; 116(8):1938-46. PubMed ID: 20166205
[TBL] [Abstract][Full Text] [Related]
11. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Zhou JB; Tang X; Han M; Yang J; Simó R
Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
[TBL] [Abstract][Full Text] [Related]
12. A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country.
Zaghloul N; Awaisu A; Mahfouz A; Alyafei S; Elewa H
Int J Clin Pharm; 2022 Dec; 44(6):1342-1350. PubMed ID: 36169802
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes.
Zhou J; Ke Y; Lei X; Wu T; Li Y; Bao T; Tang H; Zhang C; Wu X; Wang G; Li J; Zhang H; Ni F; Ye Z; Wang L
Ann Hepatol; 2020; 19(3):320-328. PubMed ID: 31980358
[TBL] [Abstract][Full Text] [Related]
14. Treatment of type 2 diabetes mellitus: pharmacologic intervention.
McCormick M; Quinn L
J Cardiovasc Nurs; 2002 Jan; 16(2):55-67. PubMed ID: 11800068
[TBL] [Abstract][Full Text] [Related]
15. Type 2 diabetes and oral antihyperglycemic drugs.
Mizuno CS; Chittiboyina AG; Kurtz TW; Pershadsingh HA; Avery MA
Curr Med Chem; 2008; 15(1):61-74. PubMed ID: 18220763
[TBL] [Abstract][Full Text] [Related]
16. Association between use of oral-antidiabetic drugs and the risk of aortic aneurysm: a nested case-control analysis.
Hsu CY; Su YW; Chen YT; Tsai SH; Chang CC; Li SY; Huang PH; Chen JW; Lin SJ
Cardiovasc Diabetol; 2016 Sep; 15(1):125. PubMed ID: 27585542
[TBL] [Abstract][Full Text] [Related]
17. Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large US administrative claims database.
Simeone JC; Quilliam BJ
Ann Pharmacother; 2012 Feb; 46(2):157-68. PubMed ID: 22234990
[TBL] [Abstract][Full Text] [Related]
18. Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
Zhang Z; Cao Y; Tao Y; E M; Tang J; Liu Y; Li F
Diabetes Res Clin Pract; 2020 Jan; 159():107990. PubMed ID: 31866530
[TBL] [Abstract][Full Text] [Related]
19. Oral combination therapy in primary care.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
[TBL] [Abstract][Full Text] [Related]
20. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease.
Donadon V; Balbi M; Ghersetti M; Grazioli S; Perciaccante A; Della Valentina G; Gardenal R; Dal Mas M; Casarin P; Zanette G; Miranda C
World J Gastroenterol; 2009 May; 15(20):2506-11. PubMed ID: 19469001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
